News

Keep up with the latest headlines in dermatology from the past week, including the discovery of a gene mutation that may cause psoriasis, the role of skin biopsies in detecting Parkinson's disease, and more.

ICYMI, this week we had news about bringing awareness to ethics in aesthetics, the 7 year anniversary of dupilumab's approval for atopic dermatitis, and more.

Learn more about the in-depth topics covered in the March 2024 print issue of Dermatology Times.

EltaMD representatives and dermatologists partook in the celebration on March 28 as a continuation of the celebration and momentum of the newly-established National Dermatologist Day.

Dermatology Times is looking back on the top stories in dermatology from the month of March.

Dermatology Times is recapping our top expert interviews from the month of March.

Researchers found that patients who initiated gender-affirming hormone therapy with testosterone were more likely to experience a worsening of their HS symptoms.

Learn more about the in-depth topics covered in the March 2024 enhancing psoriasis management supplement of Dermatology Times.

Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.

Catch up on late-breaking research shared at the 2024 American Academy of Dermatology Annual Meeting.

Researchers from Google and Stanford Medicine recently partnered to develop the Skin Condition Image Network dataset, a tool aimed at providing image resources for conditions across skin tones.

Spizuoco shares pearls from her sessions, "Infectious Diseases: The Story Behind STDs," and "Everything You Need to Know About Dermatopathology and the Dermatopathologist," from the Diversity in Dermatology conference.

In this week’s Pointers With Portela, the 208SkinDoc reveals his journey toward providing free dermatologic care through a mobile clinic.

In this month's Legal Eagle column, learn about the liabilities and how to prevent wrong-site procedures.

China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.

Moving the Needle on Ethics includes articles and interviews featuring experts in aesthetics.

This framework considers both the pregnant patient who is taking the medication and the fetus who may be exposed to it while in the womb. It assesses potential benefits and risks for both parties.

We compare 2024 Match Day statistics with data from recent years.

Up to one quarter of patients with PsA experience persistent joint pain. In a recent study, higher levels of fatigue, depression, and anxiety were associated with joint pain.

Amy B. Lewis, MD, explores the evolution of aesthetic dermatology, delving into injection sophistication, devices, and top procedures.

Click here to answer today's poll and read more about recent uses of VR in dermatology education and practice.

Positive feelings accompanying BFRBs such as dermatillomania or trichotillomania may act as an important maintenance factor, researchers wrote.

Researchers analyzed the current treatment and research landscape for CLE in a review published in the Journal of Dermatology.

By understanding employment contract essentials, dermatologists can ensure that their employment contract protects their interests and supports their career goals.

Keep up with the latest headlines in dermatology from the past week, including one dermatologist's journey with vascular birthmarks, award recipients, and more.

ICYMI, this week we had news about COVID-19 research and dermatology, Journey Medical's accepted NDA for DFD-29, late-breaking data on amlitelimab for AD, and more.

If approved, bimekizumab will be the first IL-17A and IL-17F inhibitor approved in Europe for hidradenitis suppurativa.

The paper was authored and issued by the FDA Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, and Office of Combination Products.